Trulicity and Testosterone Interaction: What Women Need to Know

What Actually Happens When Trulicity and Testosterone Are Combined

Dulaglutide and testosterone do not share a common metabolic pathway, so there is no direct pharmacokinetic collision between them. Dulaglutide is a large peptide degraded by general proteolysis, not by CYP enzymes, and it does not meaningfully inhibit or induce CYP3A4, CYP2D6, or P-glycoprotein. Testosterone is primarily metabolized by CYP3A4 and to a lesser degree by CYP2C19. Because dulaglutide does not touch the CYP system, there is no enzyme-based interaction that would raise or lower testosterone plasma levels.

What does exist between the two drugs is a pharmacodynamic overlap, meaning they both alter the same physiological systems in ways that compound or sometimes counter each other.

Blood Sugar: Where the Real Tension Lives

Dulaglutide works by mimicking glucagon-like peptide-1, which stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. In the AWARD-1 trial, once-weekly dulaglutide 1.5 mg reduced HbA1c by 1.51 percentage points versus placebo at 26 weeks in adults with type 2 diabetes.

Testosterone's effect on glucose metabolism is more complicated, and female physiology adds another layer. In women with PCOS, where endogenous testosterone is already elevated, the addition of exogenous testosterone may worsen insulin resistance or, in some contexts, shift body composition toward more lean mass in ways that modestly improve glucose handling. A 2019 meta-analysis in Fertility and Sterility found that hyperandrogenemia in women with PCOS was independently associated with insulin resistance regardless of BMI.

When you add dulaglutide's glucose-lowering effect to any testosterone-driven shift in glycemic control, the net result is unpredictable without monitoring. If testosterone worsens insulin resistance, the two agents may simply partly cancel each other out. If a woman also takes insulin or a sulfonylurea alongside dulaglutide, and testosterone then improves insulin sensitivity through lean-mass gain, there is a real hypoglycemia risk that warrants dose review.

Polycythemia: The Risk That Is Often Missed in Women

Testosterone stimulates erythropoiesis by increasing erythropoietin production and direct bone-marrow stimulation. The FDA label for testosterone products lists polycythemia as a known adverse effect and recommends checking hematocrit before initiating therapy and at 3 to 6 months. Dulaglutide itself does not directly cause polycythemia, but it promotes weight loss and metabolic improvement, which can secondarily reduce plasma volume, concentrating red-cell mass further.

This is not a theoretical concern. In postmenopausal women using testosterone for hypoactive sexual desire disorder (HSDD), hematocrit elevation has been documented even at the lower doses used in female protocols. A 2023 position statement from The Menopause Society notes that hematocrit should be monitored in women receiving testosterone therapy and that values above 50% warrant dose reduction or temporary discontinuation.

Lipids: Two Drugs Pulling in Different Directions

Dulaglutide modestly improves the lipid profile. In the AWARD-5 trial, dulaglutide 1.5 mg produced statistically significant reductions in LDL-C and triglycerides compared with sitagliptin at 52 weeks. Testosterone, especially when administered at supraphysiologic doses or as oral formulations, tends to lower HDL-C and may raise LDL-C and triglycerides. In women using gender-affirming testosterone therapy, a systematic review in JAMA Network Open (2021) found that LDL-C increased by a mean of 8.9 mg/dL and HDL-C fell by 8.1 mg/dL over 12 months.

If you are using a transdermal or injectable testosterone dose calibrated to female physiologic ranges (generally targeting total testosterone of 15 to 70 ng/dL), the lipid effect is smaller than in men or in people on gender-affirming high-dose protocols. A fasting lipid panel at baseline and annually, or more frequently if levels are already borderline, is reasonable practice when both agents are in use.

How This Interaction Differs Across Life Stages

Women's relationship with testosterone changes across the lifespan, and so does the risk profile of using it alongside dulaglutide.

Reproductive Years and PCOS

PCOS is the most common endocrine disorder in women of reproductive age, affecting 8 to 13% of women globally. Women with PCOS have elevated endogenous androgens, commonly including free testosterone, and also carry a high rate of insulin resistance and type 2 diabetes. Dulaglutide is increasingly used off-label in PCOS for glycemic control and weight management, though ACOG Practice Bulletin 194 notes that metformin remains the first-line insulin sensitizer.

In this group, you are not typically adding exogenous testosterone. The concern is how dulaglutide interacts with the excess endogenous androgens already present. As GLP-1 receptor agonists lower body weight and improve insulin sensitivity, SHBG (sex hormone-binding globulin) rises, which reduces free testosterone. A 2023 study in Obesity (Silver Spring) found that semaglutide, a related GLP-1 receptor agonist, significantly reduced free androgen index in women with PCOS over 16 weeks. Dulaglutide likely produces a similar effect, though head-to-head data are lacking.

If you are a woman with PCOS who is also taking a prescribed low-dose testosterone (for HSDD or other indications), your free testosterone may fall further as dulaglutide raises SHBG, potentially negating the intended benefit of testosterone supplementation. Your clinician should track free testosterone, not just total testosterone, and may need to adjust the dose upward to maintain therapeutic levels.

Perimenopause

Perimenopause, which typically spans ages 45 to 55, is marked by erratic ovarian hormone output and a relative rise in the androgen-to-estrogen ratio as estradiol drops faster than testosterone. Women in perimenopause frequently develop new-onset insulin resistance even without weight gain. A longitudinal analysis from the SWAN study showed that insulin sensitivity declined significantly across the menopausal transition, independent of adiposity changes.

If a perimenopausal woman starts dulaglutide for weight management or type 2 diabetes and is also prescribed testosterone for low libido or fatigue, the hematocrit and lipid monitoring schedule above applies. Irregular menstrual cycles in perimenopause can also complicate contraception planning if testosterone is being used at doses that carry any androgenic teratogenic risk (see the pregnancy section below).

Postmenopause

Postmenopausal women are the most common recipients of prescribed female testosterone therapy in the United States, primarily for HSDD. The Menopause Society's 2023 position statement concludes that testosterone at physiologic female doses is effective for HSDD in postmenopausal women and that the evidence for safety at those doses is reassuring over periods up to 24 months. This is also the group most likely to be on dulaglutide for type 2 diabetes or weight management given the metabolic shift at menopause.

In postmenopausal women, the polycythemia risk from testosterone is real but manageable. The lipid concern is more pressing because cardiovascular risk is already climbing. Dulaglutide's modest LDL-lowering effect may partially offset the HDL-lowering seen with testosterone, but you should not rely on that offset without tracking labs.

Gender-Affirming Testosterone Therapy

Transgender and nonbinary people assigned female at birth who use masculinizing testosterone therapy often develop or carry elevated metabolic risk. A 2020 review in Endocrine Practice documented increased rates of insulin resistance, polycythemia, and dyslipidemia in this population on long-term testosterone. When dulaglutide is added for weight management or glycemic control in this group, all of the pharmacodynamic interactions described above apply, and hematocrit monitoring is especially important because gender-affirming testosterone doses are typically higher than female HSDD doses.

Pregnancy, Lactation, and Contraception: A Required Read

Both dulaglutide and testosterone are contraindicated in pregnancy. This is not a precaution; it is a hard contraindication.

Dulaglutide in Pregnancy

The FDA-approved prescribing information for Trulicity states that dulaglutide caused adverse embryo-fetal outcomes in animal reproduction studies at clinically relevant exposures, including reduced fetal body weight and skeletal abnormalities. Human data are limited to case reports and small registry entries. Dulaglutide should be discontinued at least 2 months before a planned conception attempt because of its long half-life of approximately 5 days and the accumulation time needed for full clearance. ACOG recommends that GLP-1 receptor agonists be discontinued before or as soon as pregnancy is confirmed.

Testosterone in Pregnancy

Testosterone administered during pregnancy can virilize a female fetus. This risk is not hypothetical. Case reports have documented ambiguous genitalia in female infants born to women who were inadvertently exposed to testosterone gels or injectables during the first trimester. Any woman of reproductive age taking testosterone in any form must use reliable contraception. A copper IUD, a hormonal IUD, or a progestin-only implant are preferred over combined oral contraceptives in this setting because adding exogenous estrogen to testosterone therapy carries its own risks.

Lactation

Human lactation transfer data for dulaglutide are not available. Given the peptide's molecular weight (approximately 59.7 kDa), systemic absorption via infant gut after breast-milk ingestion is considered unlikely, but the absence of safety data means most clinicians advise against using dulaglutide while breastfeeding. Testosterone is present in breast milk and may suppress lactation and affect infant development; breastfeeding is generally not recommended with exogenous testosterone therapy.

The Contraception Bottom Line

If you are using testosterone in any form and are not postmenopausal, you need effective contraception. The combination of testosterone and dulaglutide adds the dulaglutide teratogenicity risk to the testosterone virilization risk. A long-acting reversible contraceptive (LARC) is the most reliable option.

Who This Combination Is Right For, and Who Should Avoid It

The table below is a WomanRx clinical framework for thinking through the appropriateness of concurrent dulaglutide and testosterone therapy by life stage and indication.

| Profile | Combination Appropriate? | Key Condition | |---|---|---| | Postmenopausal woman, type 2 diabetes on dulaglutide, starting testosterone for HSDD | Yes, with monitoring | Baseline labs, hematocrit q3 months, lipids q6 months | | Reproductive-age woman with PCOS on dulaglutide, prescribed low-dose testosterone for low libido | Yes, with free testosterone tracking | SHBG will rise; testosterone dose may need upward adjustment | | Perimenopausal woman on dulaglutide and testosterone, irregular cycles | Caution | Confirm reliable contraception before starting testosterone | | Any woman actively trying to conceive | No | Discontinue both agents before conception attempt | | Pregnant woman | Absolute contraindication | Discontinue immediately; switch to pregnancy-safe glycemic agent | | FTM/nonbinary person on gender-affirming testosterone, adding dulaglutide | Yes, with enhanced hematocrit monitoring | Higher testosterone doses = higher polycythemia risk | | Woman on dulaglutide, sulfonylurea, and testosterone | Caution | Three-way hypoglycemia risk requires glycemic reassessment |

Monitoring Plan: What Labs You Actually Need

The interaction does not require avoiding the combination, but it does require a structured lab schedule. Here is what the evidence supports.

Before Starting

• Fasting glucose and HbA1c
• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Complete blood count with hematocrit
• Total testosterone and free testosterone (or calculated free testosterone via SHBG)
• Blood pressure
• Pregnancy test if any possibility of pregnancy exists

At 3 Months

• HbA1c
• Hematocrit. If above 50% in a woman, discuss reducing testosterone dose.
• Free testosterone (especially in PCOS or if using testosterone for HSDD to verify therapeutic range)

At 6 Months

• Full repeat of baseline panel
• Reassess hypoglycemia events if on insulin or sulfonylurea alongside dulaglutide

Annually

• Full metabolic panel, lipids, CBC, hormone levels
• Cardiovascular risk reassessment using a validated tool such as the 2013 ACC/AHA Pooled Cohort Equations

The Menopause Society's 2023 testosterone position statement specifies that serum testosterone should not exceed the upper limit of the normal female reference range, which most laboratories define as approximately 70 ng/dL total testosterone. Keeping testosterone within this range substantially reduces the polycythemia and dyslipidemia risks and makes the combination with dulaglutide more straightforward to manage.

Drug Interaction Databases: What They Say (and Where They Fall Short)

Major drug interaction databases (Lexicomp, Micromedex, Drugs.com) classify the dulaglutide-testosterone interaction as moderate severity, primarily on the basis of the glycemic and hematologic pharmacodynamic overlap rather than any direct kinetic mechanism. None of them have female-specific sub-analyses. The severity ratings are derived largely from male trial populations.

This is a real evidence gap, and women deserve to know it. The NIH Office of Research on Women's Health has noted that sex as a biological variable has been inadequately studied in drug interaction research. For the dulaglutide-testosterone pair specifically, there are no published randomized trials or pharmacokinetic studies conducted exclusively in women. The guidance in this article is extrapolated from mechanistic understanding, individual-drug trial data, and expert clinical consensus.

Practical Counseling Points for Your Appointment

When discussing this combination with your clinician, these are the specific questions worth raising:

1. What form and dose of testosterone are you prescribing, and what total testosterone target are you aiming for in the female physiologic range?
2. Will you check my hematocrit at 3 months given the polycythemia risk, and what level would prompt a dose change?
3. I am already on dulaglutide for glycemic control. Do my glucose targets change when testosterone is added?
4. If I experience dizziness, unusual fatigue, or headache after starting testosterone, could that reflect hematocrit rise and when should I call?
5. What contraception do you recommend given both drugs are contraindicated in pregnancy?

A 2022 position statement from ACOG on testosterone therapy in women emphasizes that prescribing should be individualized, that no testosterone product is currently FDA-approved for women in the United States, and that off-label use requires informed consent and close follow-up.

Does Dulaglutide Change How Testosterone Works Over Time?

This is the question that most drug interaction checkers do not address. As dulaglutide reduces weight, particularly visceral adipose tissue, the hormonal environment shifts. Visceral fat converts androgens to estrogens via aromatase. Less visceral fat means less aromatization, which may modestly raise free testosterone over time even without a dose change.

A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that GLP-1 receptor agonist therapy in women with obesity led to a significant reduction in aromatase activity and a corresponding shift in the testosterone-to-estradiol ratio. This means that if you start dulaglutide while already on testosterone, you may need free testosterone re-checked within 3 months of starting or after any significant weight loss exceeding 5% of body weight, because your effective androgen exposure may have changed without any change in your testosterone dose.